FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2529235780> ?p ?o ?g. }

• W2529235780 abstract "Abstract Abstract 1368 New treatment options are necessary to improve survival rates for patients with Acute Lymphoblastic Leukemia (ALL), especially for patients with unfavorable prognostic predictors. As a new therapeutic approach specific protein kinase inhibitors are being developed that can down-regulate vital signaling pathways in leukemic blasts (McCubrey et al, 2008). The main goal of the present study is to obtain a better understanding of the kinase signaling pathways active in ALL cells and to identify potential targets for therapeutic intervention, To identify active signaling pathways in ALL we have used kinase activity arrays containing 1024 peptides representing all major signaling pathways and human proteome profiler arrays containing 46 phospho-antibodies on lysates of primary ALL blasts. In 20 patient samples a total of 10.6% 109(1024) peptides were found to be phosphorylated in 90% of the samples. About 46% 50(109). Activities for kinases including PKC, PKA, Akt, CAMK2, CDC2, CDK2, ERK, GSK3beta, JAK and MAPK were detected in these lysates. The human proteome profiler array demonstrated high levels of protein phosphorylation of CREB and RSK. We constructed a provisional signal transduction scheme of active kinases and phosphorylated proteins in ALL cells (Fig. 1A). Consistent with earlier reports, we identified a prominent role for the Raf/MEK/ERK and the PI3K/Akt/mTOR pathways in these ALL cells. Based on this provisional signal transduction scheme we composed a list of possible new druggable targets. Two proteins were selected for further investigation, CREB and RSK. Inhibition of RSK by the p90 RSK inhibitor BI-D1870 had no effect on cell viability as measured with WST-1 cell viability assay in ALL cell lines. Interestingly, inhibition of CREB by the CREB inhibitor KG-501 showed a dose- and time-dependent decrease in cell viability in all cell lines tested (LC50 values after 24h: Jurkat: 18.55 mM, Molt 4: 13.02 mM, RCH-ACV: 38.11 mM, and RS4;11 45.36 mM (Fig. 1B). LC50 values after 48h: Jurkat: 7.36 mM, Molt 4: 6.53 mM, RCH-ACV: 31.73 mM, RS4;11 36.66 mM (Fig. 1C)). In addition, apoptosis measured by AnnexinV/ PI staining showed an increased percentage of apoptotic cells in a dose- and time-dependent manner in all cell lines upon treatment with the CREB inhibitor (apoptosis after 24h: Jurkat 35.83% to 79.7%, Molt 4: 12.19% to 48.5%), RCH-ACV 11.30% to 45.9%, and RS4;11 9.84% to 19.16. Apoptosis after 48h: Jurkat 53.40% to 86.4%, Molt 4: 27.70% to 92.9%, RCH-ACV 14.07% to 63.32%, and RS4;11 7.11% to 20.75%) (Fig. 1D). To investigate the downstream effect of CREB inhibition we measured the mRNA expression of a know CREB target gene: BCL-2. Upon inhibition of CREB (50 mM KG-501) mRNA levels of BCL-2 were found to be significantly decreased compared to vehicle treated cells. In conclusion we have identified the transcription factor CREB in vitro as a potential druggable target for ALL. It is known that CREB plays an important role as a downstream target of hematopoietic growth factor signaling in hematopoiesis (Cheng et al, 2008). Based on these results, we propose CREB as a promising potential druggable target in ALL. Figure 1. (A) Provisional signal transduction scheme of active kinases and phosphorylated proteins in ALL. Green: active kinase; Yellow: phosphorylated protein; Green-Yellow: active kinase and phosphorylated protein. (B) Cell viability percentages plotted against concentration of KG-501 (mM) after 24h. (C) Cell viability percentages plotted against concentration of KG-501 (mM) after 48h. (D) Representative flow cytometric dot-plots of AnnexinV/ PI flow cytometry, inhibition of CREB induced a dose- and time-dependent apoptosis in the Molt 4 cell line. Disclosures: No relevant conflicts of interest to declare." @default.
• W2529235780 created "2016-10-14" @default.
• W2529235780 creator A5004781604 @default.
• W2529235780 creator A5005078978 @default.
• W2529235780 creator A5026402394 @default.
• W2529235780 creator A5028098938 @default.
• W2529235780 creator A5031926231 @default.
• W2529235780 creator A5035436147 @default.
• W2529235780 creator A5038325579 @default.
• W2529235780 creator A5068581233 @default.
• W2529235780 date "2011-11-18" @default.
• W2529235780 modified "2023-09-29" @default.
• W2529235780 title "Cyclic-AMP Responsive Element Binding Protein 1 (CREB) As a New Potential Druggable Target in Pediatric Acute Lymphoblastic Leukemia" @default.
• W2529235780 doi "https://doi.org/10.1182/blood.v118.21.1368.1368" @default.
• W2529235780 hasPublicationYear "2011" @default.
• W2529235780 type Work @default.
• W2529235780 sameAs 2529235780 @default.
• W2529235780 citedByCount "0" @default.
• W2529235780 crossrefType "journal-article" @default.
• W2529235780 hasAuthorship W2529235780A5004781604 @default.
• W2529235780 hasAuthorship W2529235780A5005078978 @default.
• W2529235780 hasAuthorship W2529235780A5026402394 @default.
• W2529235780 hasAuthorship W2529235780A5028098938 @default.
• W2529235780 hasAuthorship W2529235780A5031926231 @default.
• W2529235780 hasAuthorship W2529235780A5035436147 @default.
• W2529235780 hasAuthorship W2529235780A5038325579 @default.
• W2529235780 hasAuthorship W2529235780A5068581233 @default.
• W2529235780 hasConcept C104317684 @default.
• W2529235780 hasConcept C10679952 @default.
• W2529235780 hasConcept C11960822 @default.
• W2529235780 hasConcept C120504264 @default.
• W2529235780 hasConcept C1491633281 @default.
• W2529235780 hasConcept C1629964 @default.
• W2529235780 hasConcept C184235292 @default.
• W2529235780 hasConcept C29537977 @default.
• W2529235780 hasConcept C502942594 @default.
• W2529235780 hasConcept C55493867 @default.
• W2529235780 hasConcept C57074206 @default.
• W2529235780 hasConcept C62478195 @default.
• W2529235780 hasConcept C75217442 @default.
• W2529235780 hasConcept C86339819 @default.
• W2529235780 hasConcept C86554907 @default.
• W2529235780 hasConcept C86803240 @default.
• W2529235780 hasConcept C95444343 @default.
• W2529235780 hasConcept C97029542 @default.
• W2529235780 hasConceptScore W2529235780C104317684 @default.
• W2529235780 hasConceptScore W2529235780C10679952 @default.
• W2529235780 hasConceptScore W2529235780C11960822 @default.
• W2529235780 hasConceptScore W2529235780C120504264 @default.
• W2529235780 hasConceptScore W2529235780C1491633281 @default.
• W2529235780 hasConceptScore W2529235780C1629964 @default.
• W2529235780 hasConceptScore W2529235780C184235292 @default.
• W2529235780 hasConceptScore W2529235780C29537977 @default.
• W2529235780 hasConceptScore W2529235780C502942594 @default.
• W2529235780 hasConceptScore W2529235780C55493867 @default.
• W2529235780 hasConceptScore W2529235780C57074206 @default.
• W2529235780 hasConceptScore W2529235780C62478195 @default.
• W2529235780 hasConceptScore W2529235780C75217442 @default.
• W2529235780 hasConceptScore W2529235780C86339819 @default.
• W2529235780 hasConceptScore W2529235780C86554907 @default.
• W2529235780 hasConceptScore W2529235780C86803240 @default.
• W2529235780 hasConceptScore W2529235780C95444343 @default.
• W2529235780 hasConceptScore W2529235780C97029542 @default.
• W2529235780 hasLocation W25292357801 @default.
• W2529235780 hasOpenAccess W2529235780 @default.
• W2529235780 hasPrimaryLocation W25292357801 @default.
• W2529235780 hasRelatedWork W1590924049 @default.
• W2529235780 hasRelatedWork W1999046791 @default.
• W2529235780 hasRelatedWork W2004205588 @default.
• W2529235780 hasRelatedWork W2017919094 @default.
• W2529235780 hasRelatedWork W2021159608 @default.
• W2529235780 hasRelatedWork W2025416730 @default.
• W2529235780 hasRelatedWork W2035996196 @default.
• W2529235780 hasRelatedWork W2038805435 @default.
• W2529235780 hasRelatedWork W2045640927 @default.
• W2529235780 hasRelatedWork W2059075951 @default.
• W2529235780 hasRelatedWork W2062860025 @default.
• W2529235780 hasRelatedWork W2072856965 @default.
• W2529235780 hasRelatedWork W2083802789 @default.
• W2529235780 hasRelatedWork W2097092521 @default.
• W2529235780 hasRelatedWork W2106651730 @default.
• W2529235780 hasRelatedWork W2125239536 @default.
• W2529235780 hasRelatedWork W2150838629 @default.
• W2529235780 hasRelatedWork W2336651458 @default.
• W2529235780 hasRelatedWork W2349914698 @default.
• W2529235780 hasRelatedWork W2392710074 @default.
• W2529235780 isParatext "false" @default.
• W2529235780 isRetracted "false" @default.
• W2529235780 magId "2529235780" @default.
• W2529235780 workType "article" @default.